SUSAN YOUNG, SLP
Speech Language Pathology at Eubank Blvd, Albuquerque, NM

6461809, Oct 8, 2002

Apr 27, 1999

09/299625

Robert A. Hallowitz - Gaithersburg MD
Susan Young - Albuquerque NM
Chester King - Frederick MD

Bio-Tech Imaging, INC - Frederick MD

C12Q 170

435 5, 435 3, 435 4, 435 71, 435 72, 435 723, 435 724, 435 792, 436512, 436513, 436518, 436525, 436526

The present invention relates to cells which have improved receptivity to viruses which are capable of infecting them. Receptivity to such viruses is improved by selecting cells from a population which express the receptor(s) that enable a virus to attach to the cell and gain entry into it. Any combination of viruses and host cell lines can be used. In a preferred embodiment, the present invention relates to improving receptivity or infectivity of a cell line which can be infected with an immunodeficiency virus, such as HIV-1. Especially preferred embodiments of the invention relate to methods of improving (or assaying for) the infectivity for HIV-1 in a HIV-1 receptive cell line, preferably a continuous cell line transformed with DNAs coding for expressible CD4 and expressible HIV-1 coreceptor, comprising, in any effective order, a) isolating the cells expressing CD4 and an HIV-1 coreceptor on their cell surface; b) contacting the isolated cells with HIV-1 under conditions effective for the HIV-1 to infect the cells; and c) detecting the number of cells infected with HIV-1, thereby assaying for infectivity of HIV-1. This method facilitates the measurement of true infectivity and infectivity reduction values by quantifying the percentage of infected cells in the population of specific cells capable of being infected by virus, rather than in a population of mixed cells, only some which are capable of being infected.

8487100, Jul 16, 2013

Dec 14, 2010

12/967871

Eric R Prossnitz - Albuquerque NM, US
Sergey E Tkatchenko - San Diego CA, US
Chetana M Revankar - Arlington VA, US
Larry A Sklar - Albuquerque NM, US
Jeffrey B Arterburn - Las Cruces NM, US
Daniel F Cimino - Tijeras NM, US
Tudor I Oprea - Albuquerque NM, US
Bruce S Edwards - Albuquerque NM, US
Alexandor Kiselyov - San Diego CA, US
Susan M Young - Albuquerque NM, US

STC.UNM - Albuquerque NM

A61K 31/4375, C07D 221/06

546 79, 514290

The current invention is in the field of molecular biology/pharmacology and provides compounds which modulate the effects of GPR30 as well as the classical estrogen receptors alpha and beta (ERα and ERβ). These compounds may function as agonists and/or antagonists of one or more of the disclosed estrogen receptors. Diseases which are mediated through one or more of these receptors include cancer (particularly breast, reproductive and other hormone-dependent cancers, leukemia, colon cancer, prostate cancer), reproductive (genito-urological) including endometreitis, prostatitis, polycystic ovarian syndrome, bladder control, hormone-related disorders, hearing disorders, cardiovascular conditions including hot flashes and profuse sweating, hypertension, stroke, obesity, osteoporosis, hematologic diseases, vascular diseases or conditions such as venous thrombosis, atherosclerosis, among numerous others and disorders of the central and peripheral nervous system, including depression, insomnia, anxiety, multiple sclerosis, neuropathy, neurodegenerative disoders such as Parkinson's disease and Alzheimer's disease, as well as inflammatory bowel disease, Crohn's disease, coeliac (celiac) disease and related disorders of the intestine. A contraceptive indication to prevent or reduce the likelihood of pregnancy after intercourse is a further aspect of the present invention.

7875721, Jan 25, 2011

Aug 2, 2006

11/497751

Eric R. Prossnitz - Albuquerque NM, US
Sergey E. Tkatchenko - San Diego CA, US
Chetana M. Revankar - Arlington VA, US
Larry A. Sklar - Albuquerque NM, US
Jeffrey B. Arterburn - Las Cruces NM, US
Daniel F. Cimino - Tijeras NM, US
Tudor I. Oprea - Albuquerque NM, US
Bruce S. Edwards - Albuquerque NM, US
Alexander Kiselyov - San Diego CA, US
Susan M. Young - Albuquerque NM, US

STC.UNM - Albuquerque NM

A61K 31/435, C07D 221/06

546 79, 514290

The current invention is in the field of molecular biology/pharmacology and provides compounds which modulate the effects of GPR30 as well as the classical estrogen receptors alpha and beta (ERα and ERβ). These compounds may function as agonists and/or antagonists of one or more of the disclosed estrogen receptors. Diseases which are mediated through one or more of these receptors include cancer (particularly breast, reproductive and other hormone-dependent cancers, leukemia, colon cancer, prostate cancer), reproductive (genito-urological) including endometritis, prostatitis, polycystic ovarian syndrome, bladder control, hormone-related disorders, hearing disorders, cardiovascular conditions including hot flashes and profuse sweating, hypertension, stroke, obesity, osteoporosis, hematologic diseases, vascular diseases or conditions such as venous thrombosis, atherosclerosis, among numerous others and disorders of the central and peripheral nervous system, including depression, insomnia, anxiety, multiple sclerosis, neuropathy, neurodegenerative disorders such as Parkinson's disease and Alzheimer's disease, as well as inflammatory bowel disease, Crohn's disease, coeliac (celiac) disease and related disorders of the intestine. A contraceptive indication to prevent or reduce the likelihood of pregnancy after intercourse is a further aspect of the present invention.

2009020, Aug 20, 2009

Nov 28, 2008

12/315132

Richard S. Larson - Albuquerque NM, US
Larry A. Sklar - Albuquerque NM, US
Bruce S. Edwards - Albuquerque NM, US
Tudor I. Oprea - Albuquerque NM, US
Debbie M. Lovato - Albuquerque NM, US
Hadya M. Khawaja - Albuquerque NM, US
Stuart S. Winter - Albuquerque NM, US
Susan M. Young - Albuquerque NM, US

STC. UNM - Albuquerque NM

A61K 38/13, A61K 33/24, A61K 39/395, A61K 31/57, G01N 33/50, A61P 35/00

4241331, 514 11, 424649, 514179, 435 4051

Compounds disclosed which inhibit ABCB1 transporter protein are useful for treating diseases in which ABCB1 transporter protein mediates the disease state, including numerous cancers, including hematopoietic cancers, including various leukemias, especially T-lineage acute lymphoblastic leukemia, as well as cancerous tumors, especially forms which exhibit multiple drug resistance. Pharmaceutical compositions which comprise an inhibitor of ABCB1 transporter protein and at least one additional anticancer agent, optionally in combination with a pharmaceutically acceptable carrier, additive or excipient are another aspect of the present invention. A flow cytometry based, high-throughput screening (HST) assay that quantifies ABCB1 efflux is also disclosed. Methods of identifying inhibitors of ABCB1, ABCG2 and ABCC1 transporter proteins are also disclosed.

2001003, Nov 1, 2001

Mar 18, 1999

09/271430

SUSAN M. YOUNG - ALBUQUERQUE NM, US
CHESTER KING - FREDERICK MD, US
SHAWN A. MATLOCK - FREDERICK MD, US

C12N005/00, C12N005/02

435/374000, 435/325000

A process for applying and storing adherent cells on a tissue culture plate for preparing tissue culture plates for use in tissue culture experiments. In the process, adherent cells are removed from a flask using trypsin after being incubated in a COIncubator. The cell suspension is created using the adherent cells and a liquid culture medium, which is centrifuged and tested for volume using a hemacytometer. The cell suspension is placed in the wells of a tissue culture plate and then incubated. A cryopreservative is deposited into each well and the tissue culture plate is sealed with an adhesive foil cover and cryogenically preserved using liquid nitrogen. The tissue culture plate is then place into a plastic, waterproof, resealable bag enabling it to be stored at -80° C. for up to 3 months and shipped without damaging the morphological or functional nature of the adherent cells. The tissue culture plate forms part of a cryopreserved cell culture assembly which includes frozen adherent cells attached to the bottom wall surface of a well in the tissue culture plate.